Sunil Healthcare is a capsule maker that turned a simple gelatin shell into a proprietary closure system - it was the first in India to introduce double-lock and triple-lock technology, and that engineering-first instinct still defines the company five decades later. Founded in 1973 and manufacturing since 1976, it started with 200 million capsules a year and has grown into one of India’s largest hard-shell capsule producers, now operating from a single plant in Alwar, Rajasthan under the brand name ‘Sunloc’. The recurring approach is to treat the capsule not as a commodity container but as a precision delivery device - investing in multiple material technologies, international certifications, and quality systems that make it a preferred vendor to large pharmaceutical companies.
Business segments
A single-engine business built around one manufacturing platform - empty hard capsule shells - that serves pharmaceutical and nutraceutical customers through three material technologies and a common plant, brand, and quality backbone.
1. Empty hard capsule shells: the container that delivers the medicine
The company makes the two-piece shells that hold powdered drugs and supplements, selling them to large pharma companies that value reliability and closure integrity over price alone.
- Three materials, one plant - it produces traditional gelatin capsules, plant-based HPMC (hydroxypropyl methylcellulose) capsules for vegetarian and religious-compliance markets, and Pullulan capsules, all from the same Alwar facility with an installed capacity of 15 billion capsules a year.
- The lock is the differentiator - it pioneered double-lock and triple-lock technology in India, which prevents the two halves of the capsule from separating during transport and filling, a failure that would ruin a pharmaceutical batch.
- Sold as a preferred vendor, not a commodity supplier - revenue comes from large pharmaceutical companies that treat Sunil Healthcare as a preferred source, with a deliberate policy that no single customer exceeds 35% of total revenue from either domestic or export business.
- Nine sizes cover the dosing spectrum - capsules are available in sizes 00 through 5, including specialised elongated variants (0SEL and 0EL), giving formulators the full range needed for different fill weights.
- Export reach with a cost edge - roughly 21% of revenue comes from exports, and the company’s manufacturing cost in India is about a third lower than in the US, giving it a structural advantage in price-sensitive international tenders.
Quality and regulatory backbone
The company runs a quality system built to international pharmaceutical standards - not just Indian ones - which is what opens doors to regulated export markets and makes it a reliable partner for domestic pharma.
- Certifications that act as market passports - the plant is WHO-GMP certified, USFDA registered, and holds ISO 9001, ISO 14001, ISO 45001, ISO 22000, Halal, and Kosher certifications, plus ‘Star Export House’ recognition from the Indian government.
- Quality control as a production discipline - the factory uses TPAM, 5S, Jishu Hozen, Six Sigma, statistical sampling, hourly checks, automatic inspection machines, and stringent in-house specifications, all run on a SAP backbone.
- Raw-material security through supplier diversification - gelatin, the primary input, is sourced under short- to long-term contracts, and the company is actively developing suppliers outside China and at the domestic level to reduce import dependency.
- Inventory managed by criticality, not just cost - raw materials and spares are classified under a Vital, Essential, Desirable (VED) system with minimum levels hard-coded into the ERP, so a shortage of a small but critical item cannot halt a production line.
Group structure and partners
Two small overseas trading subsidiaries sit under the Indian manufacturing parent, but the operating business is entirely the Alwar plant and its 161 employees.
- North American and Mexican trading arms - Sunil Healthcare North America LLC (wholly owned, registered 2016) and Sunil Healthcare Mexico SA DE CV (99.97% owned, registered 2017) exist to trade capsules in their respective markets, though as of late 2024 they held combined assets of just Rs. 4.25 crore and generated no operating revenue in the period.
- Leadership continuity - Chairman and Managing Director Anil Kumar Khaitan has been with the family business since 1976, bringing over four decades of diversified experience across jute, paper, pharmaceutical, copper, and steel industries, while CFO Pawan Rathi handles the finance function.
- Board renewal with independence - a new Non-Executive Independent Director, Jai Prakash Singh, was appointed in February 2025 for a five-year term, and shareholders simultaneously approved the Chairman’s remuneration through March 2027.